Molecular hydrogen: New antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases

Current Pharmaceutical Design

Volumn 19, Issue 35, 2013, Pages 6375-6381

  Ishibashi, Toru ^a  

^a Hara Doi Hospital   (Japan)

Author keywords

5 ppm; 8 hydroxylguanine; Atherosclerosis; Hydroxyl radical; Molecular hydrogen; Oxidative stress; Prevention; Rheumatoid

Indexed keywords

CATALASE; COLLAGEN; DRINKING WATER; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HYALURONIC ACID; HYDROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MITOCHONDRIAL DNA; OSTEOCLAST DIFFERENTIATION FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STROMELYSIN; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; BONE DESTRUCTION; CARDIOVASCULAR RISK; CARTILAGE DEGENERATION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; INFECTION; NONHUMAN; OSTEOCLAST; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; HUMANS; HYDROGEN; INFLAMMATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84887856794     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990507     Document Type: Article

References (88)

1. Smith HS, Smith AR, Seidner P. Painful rheumatoid arthritis. Pain Physician. 2011; 14: E427-58.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
3. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm 2012 doi: 10. 1155/2012/674265.
4. Filippin LI, Vercelino R, Marroni NP, Xavier RM. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol 2012; 152: 415-22.
5. Winyard PG, Ryan B, Eggleton P, et al. Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochem Soc Trans 2011; 39: 1226-32.
6. Hadjigogos K. The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med 2003; 45: 7-13.
7. Kasai H, Crain PF, Kuchino Y, Nishimura S, Ootsuyama A, Tanooka H. Formation of 8-hydroxyguanine moiety in cellular DNA by agents producing oxygen radicals and evidence for its repair. Carcinogenesis 1986; 7: 1849-51.
8. Maki H, Sekiguchi M. MutT protein specifically hydrolyses a potent mutagenic substrate for DNA synthesis. Nature 1992; 355: 273-5.
9. Ishibashi T, Hayakawa H, Sekiguchi M. A novel mechanism for preventing mutations caused by oxidation of guanine nucleotides. EMBO Rep 2003; 4: 479-83.
10. Negishi H, Ikeda K, Kuga S, et al. The relation of oxidative DNA damage to hypertension and other cardiovascular risk factors in Tanzania. J Hypertens 2001; 19: 529-33.
11. Nishikawa T, Sasahara T, Kiritoshi S, et al. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003; 26: 1507-12.
12. Shen J, Gammon MD, Terry MB, et al. Telomere length, oxidative damage, antioxidants and breast cancer risk. Int J Cancer 2009; 124: 1637-43.
13. Bashir S, Harris G, Denman MA, Blake DR, Winyard PG. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis 1993; 52: 659-66.
14. Miyamoto M, Kotani K, Ishibashi S, Taniguchi N. The relationship between urinary 8-hydroxydeoxyguanosine and metabolic risk factors in asymptomatic subjects. Medical Principles Pract 2001; 20: 187-90.
15. Masugata H, Senda S, Murao K, et al. Association between urinary 8-Hydroxydeoxyguanosine, an indicator of oxidative stress, and the cardio-ankle vascular index in hypertensive patients. J Atheroscler Thromb 2012; 19: 747-55.
16. Mao P, Manczak M, Calkins MJ, et al. Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. Hum Mol Gen 2012; 21: 2973-90.
17. Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A. Reduction of oxidative stress, and the cardio-ankle vascular index in hypertensive marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 73-80.
18. Rall LC, Roubenoff R, Meydani SN, Han SN, Meydani M. Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) as a marker of oxidative stress in rheumatoid arthritis and aging: effect of progressive resistance training. J Nutr Biochem 2000; 11: 581-4.
19. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339: 1-9.
20. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Med 2007; 13: 688-94.
21. Gharib B, Hanna S, Abdallahi OM, Lepidi H, Gardette B, De Reggi M. Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation. C R Acad Sci III 2001; 324: 719-24.
22. Ohta S. Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications. Curr Pharm Des 2011; 17: 2241-52.
23. Ishibashi T, Sato B, Rikitake M, et al. Consumption of water containing a high concentration of molecular hydrogen reduces oxidative stress and disease activity in patients with rheumatoid arthritis: an open-label pilot study. Med Gas Res 2012; 2: 27.
24. Takahashi M. Oxidative stress and redox regulation on in vitro development of mammalian embryos. J Reprod Dev 2012; 58: 1-9.
25. Chenevier-Gobeaux C, Lemarechal H, Bonnefont-Rousselot D, Poiraudeau S, Ekindjian OG, Borderie D. Superoxide production and NADPH oxidase expression in human rheumatoid synovial cells: regulation by interleukin-1 beta and tumour necrosis factoralpha. Inflamm Res. 2006; 55: 483-90.
26. Griffiths HR. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmun Rev 2008; 7: 544-9.
27. Kundu S, Ghosh P, Datta S, Ghosh A, Chattopadhyay S, Chatterjee M. Oxidative stress as a potential biomarker for determining disease activity in patients with Rheumatoid Arthritis. Free Radic Res 2012; 46: 1482-9.
28. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552: 335-44.
29. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
30. Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta1 2006; 762: 256-65.
31. Puppo A, Halliwell B. Formation of hydroxyl radicals in biological systems. Does myoglobin stimulate hydroxyl radical formation from hydrogen peroxide? Free Radic Res Commun 1988; 4: 415-22.
32. Yang Y, Parsons KK, Chi L, Malakauskas SM, Le TH. Glutathione S-transferase-micro1 regulates vascular smooth muscle cell proliferation, migration, and oxidative stress. Hypertension 2009; 54: 1360-8.
33. Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb 2009; 16: 532-8.
34. Candeias LP, Patel KB, Stratford MR, Wardman P. Free hydroxyl radicals are formed on reaction between the neutrophil-derived species superoxide anion and hypochlorous acid. FEBS Lett 1993; 333: 151-3.
35. Gulati P, Klohn PC, Krug H, Göttlicher M, Markova B, Böhmer FD, Herrlich P. Redox regulation in mammalian signal transduction. IUBMB Life 2001; 52: 25-8.
36. Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis. Arthritis Res Ther 2004; 6: 265-78.
37. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci USA 1992; 89: 9784-8.
38. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKK alpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005; 434: 1138-43.
39. Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289: 2350-4.
40. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373: 659-72.
41. Schett G, Stach C, Zwerina J, Voll R, Manger B. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 2006; 58: 2936-48.
42. Schett G. Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity 2008; 41: 224-9.
43. Urata Y, Uesato R, Tanaka D, Nakamura Y, Motomura S. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2. 6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis 2012; 71: 534-40.
44. Lee SH, Kim TS, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Reports 2008; 41: 495-510.
45. Hitchon CA, El-Gabalawy HS. The synovium in rheumatoid arthritis. Open Rheumatol J 2011; 5: 107-14.
46. Grootveld M, Henderson EB, Farrell A, Blake DR, Parkes HG, Haycock P. Oxidative damage to hyaluronate and glucose in synovial fluid during exercise of the inflamed rheumatoid joint. Detection of abnormal low-molecular-mass metabolites by protonn. m. r. spectroscopy. Biochem J 1991; 273: 459-67.
47. Uchiyama H, Dobashi Y, Ohkouchi K, Nagasawa K. Chemical change involved in the oxidative reductive depolymerization of hyaluronic acid. J Biol Chem 1990; 265: 7753-9.
48. Hawkins CL, Davies MJ. Oxidative damage to collagen and related substrates by metal ion/hydrogen peroxide systems: random attack or site-specific damage? Biochim Biophys Acta 1997; 1360: 84-96.
49. Deberg M, Labasse A, Christgau S, et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005; 13: 258-65.
50. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
51. Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol 2010; 22: 293-8.
52. Silman AJ, MacGregor AJ, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Brit J Rheumatol 1993; 32: 903-7.
53. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
54. Willemze A, van der Woude D, Ghidey W, et al. The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis Rheum 2011; 63: 1823-32.
55. Mikuls TR, Gould KA, Bynote KK, et al. Anti-citrullinated protein antibody (ACPA) in rheumatoid arthritis: influence of an interaction between HLA-DRB1 shared epitope and a deletion polymorphism in glutathione S-transferase in a cross-sectional study. Arthritis Res Ther 2010; 12: R213.
56. Phillips DC, Dias HK, Kitas GD, Griffiths HR. Aberrant reactive oxygen and nitrogen species generation in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival, and therapeutic intervention. Antioxid Redox Signal 2010; 12: 743-85.
57. Tak PP, Zvaifler NJ, Green DR, Firestein GS. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today 2000; 21: 78-82.
58. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 2503-11.
59. Remans PH, van Oosterhout M, Smeets TJ, et al. Intracellular free radical production in synovial T lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 2005; 52: 2003-9.
60. Liu P, Demple B. DNA repair in mammalian mitochondria: Much more than we thought? Environ Mol Mutagen 2010; 51: 417-26.
61. Falkenberg M, Larsson NG, Gustafsson CM. DNA replication and transcription in mammalian mitochondria. Annual Rev Biochem 2007; 76: 679-99.
62. Schriner SE, Linford NJ, Martin GM, et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 2005; 308: 1909-11.
63. Da Sylva TR, Connor A, Mburu Y, Keystone E, Wu GE. Somatic mutations in the mitochondria of rheumatoid arthritis synoviocytes. Arthritis Res Ther 2005; 7: R844-51.
64. Ospelt C, Gay S. Somatic mutations in mitochondria: the chicken or the egg? Arthritis Res Ther 2005; 7: 179-80.
65. Ishibashi T, Hayakawa H, Ito R, Miyazawa M, Yamagata Y, Sekiguchi M. Mammalian enzymes for preventing transcriptional errors caused by oxidative damage. Nucleic Acids Res 2005; 33: 3779-84.
66. Cavagna L, Boffini N, Cagnotto G, Inverardi F, Grosso V, Caporali R. Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediators Inflamm 2012; doi: 10. 1155/2012/147354.
67. Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010; 212: 377-82.
68. Takac I, Schroder K, Brandes RP. The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr Hypertens Rep 2012; 14: 70-8.
69. Montezano AC, Touyz RM. Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin Pharmacol Toxicol 2012; 110: 87-94.
70. Al Ghouleh I, Khoo NK, Knaus UG, et al. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med 2011; 51: 1271-88.
71. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
72. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000; 20: 1716-23.
73. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta 2010; 411: 1875-82.
74. Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE. Intra-arterial tumor necrosis factor-alpha impairs endotheliumdependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 2003; 23: 695-701.
75. Szekanecz Z, Kerekes G, Soltesz P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009; 5: 677-84.
76. Goebel KM, Storck U, Neurath. Intrasynovialorgote in therapy in rheumatoid arthritis. Lancet 1981; 1: 1015-17.
77. Arii K, Kumon Y, Ikeda Y, Suehiro T, Hashimoto K. Edaravone inhibits the disease activity in rheumatoid arthritis. J Clin Pharm Ther 2006; 31: 197-9.
78. Salvemini D, Cuzzocrea S. Therapeutic potential of superoxide dismutase mimetics as therapeutic agents in critical care medicine. Crit Care Med 2003; 31: S29-38.
79. Afonso V, Champy R, Mitrovic D, Collin P, Lomri A. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 2007; 74: 324-9.
80. Ohno K, Ito M, Ichihara M. Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases. Oxid Med Cell Longev 2012; doi: 10. 1155/2012/353152.
81. Nakao A, Toyoda Y, Sharma P, Evans M, Guthrie N. Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. J Clin Biochem Nutr 2010; 46: 140-9.
82. Nakayama M, Kabayama S, Nakano H, et al S. Biological effects of electrolyzed water in hemodialysis. Nephron Clin Pract 2009; 112: c9-15.
83. Kajiyama S, Hasegawa G, Asano M, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res 2008; 28: 137-43.
84. Ito M, Ibi T, Sahashi K, Ichihara M, Ohno K. Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies. Med Gas Res 2011; 1: 24.
85. Ono H, Nishijima Y, Adachi N, et al. Improved brain MRI indices in the acute brain stem infarct sites treated with hydroxyl radical scavengers, Edaravone and hydrogen, as compared to Edaravone alone. A non-controlled study. Med Gas Res 2011; 1: 12.
86. Abraini JH, Gardette-Chauffour MC, Martinez E, Rostain JC, Lemaire C. Psychophysiological reactions in humans during an open sea dive to 500 m with a hydrogen-helium-oxygen mixture. J Appl Physiol 1994; 76: 1113-8.
87. Fontanari P, Badier M, Guillot C, et al. Changes in maximal performance of inspiratory and skeletal muscles during and after the 7. 1-MPa Hydra 10 record human dive. Eur J Appl Physiol 2000; 81: 325-8.
88. Nakai Y, Sato B, Ushiama S, Okada S, Abe K, Arai S. Hepatic oxidoreduction-related genes are upregulated by administration of hydrogen-saturated drinking water. Biosci Biotechnol Biochem 2011; 75: 774-6.